Lung Cancer

Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Squamous Non-Small Cell Lung Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced fr...

$2,000.00

Interstitial Lung Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 15:44:46 +0000

Summary

Interstitial Lung Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Interstitial Lung Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprie...

$2,000.00

Lung Cancer Treatment Drugs Industry Forecasts - China Focus

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Lung Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minima...

$1,800.00

Lung Cancer Treatment Drugs Companies in China

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Lung Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry i...

$1,800.00

Small Cell Lung Cancer - Pipeline Insight, 2021

Fri, 19 Mar 2021 14:59:26 +0000

DelveInsight’s, “Small Cell Lung Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Small Cell Lung Cancer Understanding Small Cell Lung Cancer: Overview Small cell lung cancer accounts only for 13% of the lung cancers. However, SCLC is the more aggressive form of lung cancer. With SCLC, the cancer cells tend to grow quickly and travel to other parts of the body, or metastasize, more easily. Small cell lung cancer is more strongly linked to smoking. Small cell lung cancer typically have had relatively very few symptoms. The symptoms can result from local growth of the tumor, spread to nearby areas, distant spread, paraneoplastic syndromes, or a combination the...

$3,000.00

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage C-MET Non-Small Cell Lung Cancer Understanding C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC): Overview The role of the c-mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in Non-Small Cell Lung Cancer both in preclinical and in clinical trials. However, given the molecular heterogeneity of Non-Small Cell Lung Cancer, it is likely that only a specific subset of Non-Small Cell Lung Cancer patients will benefit from c-MET in...

$2,000.00

BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Non-Small Cell Lung Cancer Understanding Non-Small Cell Lung Cancer (NSCLC): Overview Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognos...

$1,500.00

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Non-Small Cell Lung Cancer Understanding Non-Small Cell Lung Cancer (NSCLC): Overview Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) ar...

$2,000.00

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage ALK-positive Non-Small Cell Lung Cancer Understanding ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Overview ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it's a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than ...

$2,000.00

Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Non-Small Cell Lung Cancer Understanding Non-Small Cell Lung Cancer (NSCLC): Overview Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often simila...

$5,000.00

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020

Mon, 24 Feb 2020 15:56:48 +0000

Summary

GlobalData's clinical trial report, “Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Small-Cell Lung Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Small-Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategi...

$2,500.00

Squamous Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2018

Wed, 17 Oct 2018 16:06:20 +0000

Summary

GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Squamous Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps t...

$2,500.00

Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H2, 2018

Wed, 17 Oct 2018 16:06:20 +0000

Summary

GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H2, 2018" provides an overview of Squamous Non-Small Cell Lung Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities an...

$2,500.00

Small-Cell Lung Cancer - Pipeline Review, H2 2017

Fri, 26 Jan 2018 11:25:24 +0000

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases....

$2,000.00

Small cell lung cancer (SCLC)"- Market Insights, Epidemiology and Market Forecast-2020

Fri, 26 Jan 2018 11:14:37 +0000

Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and global market trends of the %Indication% for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Small cell lung cancer (SCLC) forecasted market share for ten years to 2020 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Small cell lung cancer (SCLC) till 2020. Key Coverage and Benefits The report will help in developing business strategies by understanding the trends shaping and driving the global Small cell lung cancer (SCLC) market. Identifying patient populations in the global “Small cell lung cancer (SCLC)market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the best opportunities for Small cell lung cancer (SCLC) therapeutics in each of the markets covered. To understand the future ...

$4,950.00

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025

Fri, 28 Apr 2017 12:22:18 +0000

Summary

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (IARC, 2016). Lung cancer is classified into three main types: non-small cell lung cancer (NSCLC), small cell lung cancer, and lung carcinoid tumor. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. Small cell lung cancer accounts for 10-15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than 5% of lung cancers.

In the 8MM, the diagnosed incident cases of NSCLC will increase from 791,563 cases in 2015 to 1,069,516 cases in 2025, at an Annual Growth Rate (AGR) of 3.51% per year. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed incident cases of NSCLC during the forecast period. In 2015, there were 1,199,845 five-year diagnosed prevalent cases of NSCLC in the 8MM, which is expected to increase to 1,626,132 cases by 2025, at an AGR of 3.55%.

The relative survival of NSCLC varies b...

$3,995.00

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Fri, 28 Apr 2017 10:35:57 +0000

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the curre...

$4,995.00

Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

Mon, 20 Mar 2017 10:44:29 +0000

Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine. For the purposes of this report, the author considers the Global NSCLC market to include NSCLC-specific drug sales in the 8MM (US, 5EU [France, Germany Italy, Spain, and the UK], Japan, and China). The current market across these countries is dominated by the sale of major chemotherapy regimens, anti-angiogenic agents and targeted therapies for patients with EGFR+ and ALK+ NSCLC. The author estimated that the Global NSCLC market was valued at $6.2b in 2015. The NSCLC therapeutics market is e...

$10,995.00

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024

Mon, 10 Oct 2016 12:19:19 +0000

Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades....

$10,995.00

Small cell lung cancer (SCLC)- Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Small cell lung cancer (SCLC) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Small cell lung cancer (SCLC) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Small cell lung cancer (SCLC) market. • Identifying patient populations in the global “Small cell lung cancer (SCLC)market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Small cell...

$4,950.00

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Wed, 01 Jun 2016 12:01:40 +0000

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ...

$4,995.00